TG Therapeutics’ $300 Million Upsized Common Stock Offering

Alston & Bird LLP advised TG Therapeutics on the deal, while Cravath represented the underwriters. TG Therapeutics, a biopharmaceutical company developing novel treatments for certain blood…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here